A polyphenolic fraction from grape seeds causes irreversible growth inhibition of breast carcinoma MDA-MB468 cells by inhibiting mitogen- activated protein kinases activation and inducing G1 arrest and differentiation

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2921-2930

  Agarwal, Chapla ^a   Sharma, Yogesh ^a   Zhao, Jifu ^a   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; DNA FRAGMENT; MITOGEN ACTIVATED PROTEIN KINASE; PLANT EXTRACT; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROCYANIDIN;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; ENZYME INHIBITION; GRAPE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLAVONOIDS; FRUIT; G1 PHASE; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENOLS; POLYMERS; SEEDS; TUMOR CELLS, CULTURED;

EID: 0033941122     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Cancer Facts and Figures - 1999. American Cancer Society, Inc., 2000.
2. Singh, D. K., and Lippman, S. M. Cancer chemoprevention. Part 1: retinoids and carotenoids and other classic antioxidants. Oncology, 12: 1643-1659, 1998.
3. Singh, D. K., and Lippman, S. M. Cancer chemoprevention. Part 2: hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents. Oncology, 12: 1787-1800, 1998.
4. Kelloff, G. J., Boone, C. W., Crowell, J. A., Steele, V. E., Lubet, R., and Sigman C. C. Chemopreventive drug development: prospectives and progress. Cancer Epidemiol. Biomark. Prev., 3: 85-98, 1994.
5. Kelloff, G. J., Boone, C. W., Crowell, J. A., Nayfield, S. G., Hawk, E., Malone, W. F., Steele, V. E., Lubet, R. A., and Sigman, C. C. Risk biomarkers and current strategies for cancer chemoprevention. J. Cell. Biochem., 25S: 1-14, 1996.
6. Birt, D. F., Felling, J. C., Nair, S., and Lepley, D. Diet intervention for modifying cancer risk. Prog. Clin. Biol. Res., 395: 223-234, 1996.
7. Morse, M. A., and Stoner, G. D. Cancer chemoprevention: principles and prospects. Carcinogenesis (Lond.), 14: 1737-1746, 1993.
8. Lipkin, M. New rodent models for studies of chemopreventive agents. J. Cell. Biochem. Suppl., 28-29: 144-147, 1997.
9. Conney, A. H., Lou, Y. R., Xie, J. G., Osawa, T., Newmark, H. L., Liu, Y., Chang, R. L., and Huang, M. T. Some perspectives on dietary inhibition of carcinogenesis: studies with curcumin and tea. Proc. Soc. Exp. Biol. Med., 216: 234-245, 1997.
10. Goodman, G. E. The clinical evaluation of cancer prevention agents. Proc. Soc. Exp. Biol. Med., 216: 253-259, 1997.
11. Boone, C. W., Bacus, J. W., Bacus, J. V., Steele, V. E., and Kelloff, G. J. Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents. J. Cell. Biochem. Suppl., 28-29: 1-20, 1997.
12. Hong, W. K., and Sporn, M. B. Recent advances in chemoprevention of cancer. Science (Washington DC), 278: 1073-1077, 1997.
13. Wattenberg, L. W. An overview of chemoprevention: current status and future prospects. Proc. Soc. Exp. Biol. Med., 216: 133-141, 1997.
14. Perchellet, J-P., and Perchellet, E. M. Antioxidants and multistage carcinogenesis in mouse skin. Free Radic. Biol. Med., 7: 377-408, 1989.
15. Dragsted, L. O. Natural antioxidants in chemoprevention. Arch. Toxicol. Suppl., 20: 209-226, 1998.
16. Mukhtar, H., and Agarwal, R. Skin cancer chemoprevention. J. Invest. Dermatol. Symp. Proc., 1: 209-214, 1996.
17. Hocman, G. Prevention of cancer: vegetables and plants. Comp. Biochem. Physiol. B, 93: 201-212, 1989.
18. Yang, C. S., Lee, M. J., Chen, L., and Yang, G. Y. Polyphenols as inhibitors of carcinogenesis. Environ. Health Perspect., 105 (Suppl 4): 971-976, 1997.
19. Singleton, V. L. Tannins and the qualities of wines. In: P. E. Laks and R. W. Hemingway (eds.), Plant Polyphenols, pp. 859-880. New York: Plenum Press, 1992.
20. Agarwal, R., Katiyar, S. K., Zaidi, S. I. A., and Mukhtar, H. Inhibition of skin tumor promoter-caused induction of epidermal ornithine decarboxylase in SENCAR mice by polyphenolic fraction isolated from green tea and its individual epicatechin derivatives. Cancer Res., 52: 3582-3588, 1992.
21. Bartolome, B., Hernandez, T., Bengoechea, M. L., Quesada, C., Gomez-Cordoves, C., and Estrella, I. Determination of some structural features of procyanidins and related compounds by photodiode-array detection. J. Chromatography A, 723: 19-26, 1996.
22. Escribano-Bailon, M. T., Gutierrez-Fernandez, Y., Rivas-Gonzalo, J. C., Santos-Buelga, C. Characterization of procyanidins of Vitis vinifera variety Tinta del Paris grape seeds. J. Agric Food Chem., 40: 1794-1799, 1992.
23. Maffei Facino, R., Carini, M., Aldini, G., Berti, F., Rossoni, G., Bombardelli, E., and Morazzoni, P. Procyanidines from Vitis vinifera seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. Planta Med., 62: 495-502, 1996.
24. Bagchi, D., Garg, A., Krohn, R. L., Bagchi, M., Bagchi, D. J., Balmoori, J., and Stohs, S. J. Protective effects of grape seed proanthocyanidins and selected antioxidants against TPA-induced hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macrophage activation in mice. Gen. Pharmacol., 30: 771-776, 1998.
25. Halpern, M. J., Dahlgren, A. L., Laakso, I., Seppanen-Laakso, T., Dahlgren, J., and McAnulty, P. A. Red-wine polyphenols and inhibition of platelet aggregation: possible mechanisms, and potential use in health promotion and disease prevention. J. Int. Med. Res., 26: 171-180, 1998.
26. Soleas, G. J., Diamandis, E. P., and Goldberg, D. M. Wine as a biological fluid: history, production, and role in disease prevention. J. Clin. Lab. Anal., 11, 287-313, 1997.
27. Min mouse. Proc. Am. Assoc. Cancer Res. Annu. Meet., 39: 20, 1998.
28. Bomser, J. A., Singletary, K. W., Wallig, M. A., and Smith, M. A. L. Inhibition of TPA-induced tumor promotion in CD-1 mouse epidermis by a polyphenolic fraction from grape seeds. Cancer Lett., 135: 151-157, 1999.
29. Zhao, J., Wang, J., Chen, Y., and Agarwal, R. Anti-tumor promoting activity of a polyphenolic fraction isolated from grape seeds in mouse skin two-stage initiation-promotion protocol, and identification of procyanidin B5-3′-gallate as the most effective antioxidant constituent. Carcinogenesis (Lond.), 20: 1737-1745, 1999.
30. Zheng, T., Boyle, P., Willett, W. C., Hu, H., Dan, J., Evstifeeva, T. V., Niu, S., and MacMahon, B. A case-control study of oral cancer in Beijing, People's Republic of China. Associations with nutrient intakes, foods and food groups. Eur. J. Cancer B Oral Oncol., 29B: 45-55, 1993.
31. Shackney, S. E., Pollice, A. A., Smith, C. A., Janocko, L. E., Sweeney, L., Brown, K. A., Singh, S. G., Gu, L., Yakulis, R., and Lucke, J. F. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients. Clin. Cancer Res., 4: 913-928, 1998.
32. Clark, G. J., and Der, C. Aberrant function of the Ras signal pathway in human breast cancer. Breast Cancer Res. Treat., 35: 133-144, 1995.
33. Sepp-Lorenzino, L., Eberhard, I., Ma, Z., Cho, C., Serve, H., Liu, F., Rosen, N., and Lupu, R. Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Oncogene, 12: 1679-1687, 1996.
34. Goldman, R., Levy, R. B., Peles, E., and Yarden, Y. Heterodimerization of the erbB1 and erbB2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry, 29: 11024-11028, 1990.
35. Resnik, J. L., Reichart, D. B., Huey, K., Webster, N. J. G., and Seeley, B. L. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res., 58: 1159-1164, 1998.
36. Earp, H. S., Dawson, T. L., Li, H., and Yu, H. Heterodimerization and functional interaction between EGF receptor family member: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat., 35: 115-132, 1995.
37. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.
38. Monteiro, H. P., and Stern, A. Redox modulation of tyrosine phosphorylation-dependent signal transduction pathways. Free Radic. Biol. Med., 21: 323-333, 1996.
39. Sen, C. K., and Packer, L. Antioxidants and redox regulation of gene transcription. FASEB J., 10: 709-720, 1996.
40. Canman, C. E., and Kastan, M. B. Three paths of stress relief. Nature (Lond.), 384: 213-214, 1996.
41. Carpenter, G., and Cohen, S. Epidermal growth factor. J. Biol. Chem., 265: 7709-7712, 1990.
42. Groom, L. A., Sneddon, A. A., Alessi, D. R., Dowd, S., and Keyse, S. M. Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO J., 15: 3621-3632, 1996.
43. 2-terminal kinase. Proc. Natl. Acad. Sci. USA, 94: 7337-7342, 1997.
44. Gerwins, P., Blank, J. L., and Johnson, G. L. Cloning of a novel mitogen-activated protein kinase kinase kinase, MEKK4, that selectively regulates the c-Jun amino terminal kinase pathway. J. Biol. Chem., 272: 8288-8295, 1997.
45. Whitmarsh, A. J., Cavanagh, J., Tournier, C., Yasuda, J., and Davis, R. J. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science (Washington DC), 281: 1671-1674, 1998.
46. Hoffmeyer, A., Grosse-Wilde, A., Flory, E., Neufeld, B., Kunz, M., Rapp, U. R., and Ludwig, S. Different mitogen-activated protein kinase signaling pathways cooperate to regulate tumor necrosis factor a gene expression in T lymphocytes. J. Biol. Chem., 274: 4319-4327, 1999.
47. Abe, M. K., Kuo, W-L., Hershenson, M. B., and Rosner, M. R. Extracellular signal-regulated kinase 7 (ERK7), a novel ERK with a C-terminal domain that regulates its activity, its cellular localization, and cell growth. Mol. Cell. Biol., 19: 1301-1312, 1999.
48. Di Marco, E., Pierce, J. H., Fleming, T. P., Kraus, M. H., Molloy, C. J., Aaronson, S. A., and Di Fiore, P. P. Autocrine interaction between TGFα and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene, 4: 831-838, 1989.
49. Sivaraman, V. S., Wang, H., Nuovo, G. J., and Malbon, C. C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest., 99: 1478-1483, 1997.
50. Lange, C. A., Richer, J. K., Shen, T., and Horwitz, K. B. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J. Biol. Chem., 273: 31308-31316, 1998.
51. Coutts, A. S., and Murphy, L. C. Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res., 58: 4071-4074, 1998.
52. Salh, B., Marotta, A., Matthewson, C., Ahluwalia, M., Flint, J., Owen, D., and Pelech, S. Investigation of the Mek-MAP kinase Rsk pathway in human breast cancer. Anticancer Res., 19: 731-740, 1999.
53. 1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of CDKs and associated cyclins. Clin. Cancer Res., 4: 1055-1064, 1998.
54. Zi, X., and Agarwal, R. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin. Biochem. Biophys. Res. Commun., 263: 528-536, 1999.
55. Cobb, M. H., and Goldsmith, E. J. How MAP kinases are regulated. J. Biol. Chem., 270: 14843-14846, 1995.
56. Chen, Y. R., Wang, X., Templeton, D., Davis, R. J., and Tan, T. H. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and γ radiation. Duration of JNK activation may determine cell death and proliferation. J. Biol. Chem., 277: 31929-31936, 1996.
57. Seger, R., and Krebs, E. G. The MAPK signaling cascade. FASEB J., 9: 726-735, 1995.
58. Jacks, T., and Weinberg, R. A. Cell-cycle control and its watchman. Nature (Lond.), 381: 643-644, 1996.
59. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
60. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
61. Weinstein, I. B. Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. J. Cell. Biochem., 25S: 23-28, 1996.
62. Grana, X., and Reddy, P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CDKIs). Oncogene, 11: 211-219, 1995.
63. Liu, Y., Martindale, J. L., Gorospe, M., and Holbrook, N. J. Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res., 56: 31-35, 1996.
64. Jing, Y., Zhang, J., Waxman, S., and Mira-y-Lopez, R. Up-regulation of cytokeratins 8 and 18 in human breast cancer T47D cells is retinoid-specific and retinoic acid receptor-dependent. Differentiation, 60: 109-117, 1996.
65. Yao, R., Yoshihara, M., and Osada, H. Specific activation of a c-Jun NH2-terminul kinase isoform and induction of neunte outgrowth in PC-12 cells by staurosporine. J. Biol. Chem., 272; 18261-18266, 1997.
66. Yuasa, T., Ohno, S., Kehrl, J. H., and Kyriakis, J. M. Tumor necrosis factor signaling to stress-activated protein kinases (SAPK)/Jun HH2-terminal kinase (JNK) and p38. J. Biol. Chem., 273: 22681-22692, 1998.
67. Smith, J. A., Poteet-Smith, C. E., Malarkey, K., and Sturgill, T. W. Identification of an extracellular signal-regulated kinase (ERK) docking site in ribosomal S6 kinase, a sequence critical for activation by ERK in vivo. J. Biol. Chem., 274: 2893-2898, 1999.
68. Kulik, G., Klippel, A., and Weber, M. J. Antiapoptotic signalling by insulin-like growth factor-1 receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol., 17: 1595-1606, 1997.
69. Xiaong, Y. Why are there so many CDK inhibitors. Biochim. Biophys. Acta, 1288: 1-5, 1996.
70. Guo, K., Wang, J., Andres, V., Smith, R. C., and Walsh, K. MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol. Cell. Biol., 15: 3823-3829, 1995.
71. Missero, C., Calautti, E., Eckner, R., Chin, J., Tsai, L. H., Livingston, D. M., and Dotto G. P. Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc. Natl. Acad. Sci. USA, 92: 5451-5455, 1995.
72. Jiang, H., Lin, J., Su, Z., Herlyn, M., Kerbel, R. S., Weissman, B. E., Welch, D. R., and Fisher, P. B. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene, 10: 1855-1864, 1995.
73. Kip1 accumulation during the cell cycle. Science (Washington DC), 271: 1861-1864, 1996.
74. Cox, M. E., Deeble, P. D., Lakhani, S., and Parsons, S. J. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res., 59: 3821-3830, 1999.